Bapineuzumab Failure May Signal Bleak Outlook for Alzheimer’s Drugs

Pfizer, Johnson & Johnson and Elan’s termination of their late-stage program for investigational Alzheimer’s drug bapineuzumab following the second failed study may not negatively impact the companies but could foreshadow a bleak outlook for the future of Alzheimer’s drug development, analysts say. Though the bapineuzumab failure was not unexpected, it may deter drugmakers from Alzheimer’s research, Leerink Swann analyst Seamus Fernandez wrote in an Aug. 7 note.
Clinical Trials Advisor